proval from, the Animal Care Committee of Yamagata University School of Medicine.
Transgenic Mice
Heterozygotic transgenic mice of the strain TgHS/SF-218, which carry the human CuZn-SOD gene (SOD1), produced as described by Epstein, et al., 8 were maintained in specific pathogen-free conditions and fed standard mouse chow ad libitum. Transgenic and wild-type mice were identified using polymerase chain reaction analysis of genomic DNA. In transgenic mice, CuZn-SOD activity was threefold that in wild-type mice. 8 
Experiment 1: Assessment of NSCs in Aging Mice
In this study of chronic oxidative stress, we compared 3-and 16-month-old male transgenic and wild-type mice (five rats in each group).
Experiment 2: Assessment of NSCs in Mice Exposed to Transient Focal Cerebral Ischemia
To induce transient focal cerebral ischemia, 3-month-old male transgenic and wild-type mice weighing 28 to 34 g were subjected to 30-minute MCAOs (seven animals per group). 27, 43 They were intraperitoneally injected with xylasine (2 mg/kg) and anesthetized with 1 to 2% sevoflurane, 66% O 2 , and 33% N 2 O during the operation. Their rectal temperature was maintained at 37 Ϯ 0.5˚C by using a homeothermic blanket control unit (Harvard Apparatus, Holliston, MA). The intraluminal suture method was used to occlude the middle cerebral artery. 27 The left common carotid artery and ECA were exposed, and the ECA and its branches were coagulated. A 5-0 nylon suture, rounded at the tip, was inserted into the ECA and advanced 9 to 10 mm past the bifurcation of the common carotid artery. Following the 30-minute occlusion, the suture was removed; all mice manifested right hemiparesis. All surgical procedures were conducted by one of the authors (A.K.), who had been blinded to the transgenic or wild-type nature of the animals.
Evaluation of NSCs
Labeling With BrdU. Bromodeoxyuridine was intraperitoneally administered (50 mg/kg) on the day before killing the animals.
Immunohistochemical Analysis. At 24 hours after the administration of BrdU, the animals received an ethylether inhalation overdose. They were then transcardially perfused with 4% paraformaldehyde in 0.1 M phosphate buffer, and their brains were removed and immersed in 4% paraformaldehyde in 0.1 M phosphate buffer for 2 hours for postfixation and stored in 30% sucrose with alabia gum. Coronal tissue sections (30 m thick) were cut using a cryostat at Ϫ20˚C and stored in 0.1 M PBS. The sections were soaked for 2 hours at room temperature in 0.3% Triton X-100 in PBS. For immunohistochemical detection of BrdU in cell nuclei, DNA was denuded to expose the antigen. Brain sections were pretreated with 50% formamide/280 mM NaCl/30 mM sodium citrate at 65˚C for 2 hours, incubated at 37˚C for 30 minutes in 2N-HCl, and then incubated with the primary anti-BrdU antibody. The sections were rinsed in 0.1 M boric acid (pH 8.5) for 10 minutes at room temperature, incubated for 30 minutes in 0.1% normal goat serum, and rinsed three times in 5-minute PBS washes. They were then incubated overnight at room temperature with the primary antibody diluted in PBS/0.1% normal goat serum/0.3% Triton X-100, washed in PBS, and incubated with the biotinylated secondary antibody (30 minutes at room temperature). After three 5-minute rinses in PBS, the sections were placed in avidin-biotin complex solution for 30 minutes at room temperature. After three additional 5-minute PBS rinses, the tissues were incubated for 5 to 10 minutes in a peroxidase reaction solution (0.25 mg/ml diaminobenzidine, and 0.01% H 2 0 2 in Tris-HCl buffer [pH 7.5]).
Double Immunohistochemical Analysis. Following DNA denudation, brain tissue sections were incubated overnight with primary antibody diluted with PBS/0.1% normal goat serum/0.3% Triton X-100 at room temperature. The primary antibodies consisted of a mouse monoclonal anti-BrdU antibody (1 g/ml; Roche, Basel, Switzerland), rat monoclonal anti-BrdU antibody (1 m/ml; Abcom, Cambridge, United Kingdom), mouse monoclonal anti-NeuN antibody (1 m/ml; Chemicon, Temecula, CA), rabbit polyclonal anti-GFAP antibody (1 g/ml; DAKO, Glostrup, Denmark), biotin-conjugated IB-4 antibody (5 m/ml; Molecular Probes, Eugene, OR), and mouse monoclonal anti-PCNA antibody (1 m/ml; Santa Cruz Biotechnology, Santa Cruz, CA). For double-labeling of BrdU and cell markers (NeuN, mature neurons; GFAP, astrocytes; IB-4, microglia; and PCNA, immature neurons), sections were incubated with anti-BrdU antibody and cell marker-specific antibodies.
The secondary antibodies consisted of biotinylated anti-mouse, anti-rat, and anti-rabbit immunoglobulin antibody (5 g/ml; Vector Laboratories, Burlingame, CA). The sections were incubated in secondary antibodies diluted with PBS/0.05% Tween-20 at room temperature for 30 minutes and then washed with PBS three times for 7 minutes each time. Tertiary antibodies included anti-mouse immunoglobulin antibody (Alexa FluorTM 488 and 546 conjugated), and streptavidin (Alexa Fluor 488 and 546 conjugated; Molecular Probes).
Cell Counting. Figure 1 shows the area where BrdU-positive cells were counted. Sections for SVZ assessment were located 0.2 mm in front of the bregma, whereas sections for DG assessment were located 1.7 mm behind the bregma. Cells were counted using a microscope; their numbers in five consecutive coronal sections from each mouse were averaged. Fluorescence was detected using a Qfluoro V3.0 fluorescence microscope (Leica Microsystems, Tokyo, Japan) equipped with a krypton-argon laser. Images obtained by averaging five scans were processed using Photoshop software (Adobe Systems, Mountain View, CA).
Statistical Analysis
Results were expressed as the means Ϯ standard deviations. The difference between old and young mice in the transgenic and wildtype groups was analyzed with an unpaired t-test in Experiment 1. Statistical analysis was performed using ANOVA and the post hoc comparisons (Student-Newman-Keuls test) to compare BrdU-positive cells in the SVZ and DG in ischemic and nonischemic hemispheres and in controls in Experiment 2. Differences were considered significant at a probability value less than 0.05. ic images of immunohistochemical staining for BrdU in the SVZ and DG, respectively. Note that BrdU staining was significantly stronger in 3-month-old than in 16-month-old mice, regardless of whether they were transgenic or wild type. In 3-month-old wild-type and transgenic mice, there was no significant difference in the number of BrdU-positive cells in the SVZ (275.1 Ϯ 64.5 compared with 285.4 Ϯ 87.7 cells, respectively; Fig. 2e ) and DG (12.2 Ϯ 2.7 compared with 13.2 Ϯ 6.4 cells, respectively; Fig. 3e ). On the other hand, in the SVZ in 16-month-old animals, transgenic mice had significantly more BrdU-positive cells than did wild-type mice (97.4 Ϯ 12.5 compared with 44.1 Ϯ 11.8 cells, respectively; p Ͻ 0.05). There was no significant difference in the DG (6.8 Ϯ 2.2 compared with 4.8 Ϯ 2.2 cells, respectively).
Results

Experiment 1: Assessment of NSCs in the Course of Aging
Experiment 2: Assessment of NSCs Following Transient Focal Cerebral Ischemia
As shown in Fig. 4 , there was no significant difference in the infarct volume between transgenic and wild-type mice 8 days after ischemia (18.4 Ϯ 16.5 compared with 20.7 Ϯ 15.9 mm 3 , respectively). The infarct area lay mainly in the basal ganglia; the cerebral cortex was not infarcted.
Figure 5a to d is representative of immunohistochemical staining for BrdU in the SVZ in mice exposed to transient ischemia and in sham-operated controls. The number of BrdU-positive cells in the SVZ in the ischemic hemisphere was significantly greater than that in the SVZ in the nonischemic hemisphere and in sham-operated controls (Table  1) . There was no significant difference in the number of BrdU-positive cells in the SVZ in the nonischemic hemisphere and in controls. Furthermore, transgenic and wildtype mice manifested no significant difference in the number of BrdU-positive cells in the bilateral SVZ following transient ischemia (Fig. 5e) . Figure 6a to d is representative of immunohistochemical staining for BrdU in the DG. The number of BrdU-positive cells in the DG on the ischemic side was significantly greater than that in the nonischemic hemisphere and in shamoperated controls (Table 2 ). There was no significant difference in the number of BrdU-positive cells in the DG between the nonischemic side and in the controls (Fig. 6e) . Note, however, that transgenic mice manifested significantly more BrdU-positive cells in the DG than did the wildtype mice (p Ͻ 0.05).
Double Immunohistochemical Analysis in the DG of Ischemic Mice
Approximately 10% of the BrdU-positive cells were colocalized with NeuN, a marker of mature neurons; more than 90% were colocalized with PCNA, a marker of proliferative cells (Fig. 7) . Fewer than 5% of these cells were colocalized with GFAP, a marker of astrocytes, and none were colocalized with IB-4, a marker of microglia. These ratios did not differ significantly in both groups of mice.
Discussion
Chronic Oxidative Stress
Kuhn, et al., 22 reported that the proliferation of NSCs is age dependent and hypothesized that in the course of aging, the local environment of the precursor cells changes so
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Copper/zinc superoxide dismutase and neural stem cells that mitotic stimuli are no longer present. The underlying mechanism of this change remains to be elucidated, however. Huang, et al., 14 observed no difference in the lifespan of transgenic and wild-type mice overexpressing SOD1. Therefore, oxidative stress is just one of the factors attributable to aging.
In our study, we used 16-month-old mice to analyze chronic oxidative stress. We found that the transgenic mice tended to have more NSCs in the DG than those in agematched wild-type mice (6.8 Ϯ 2.2 compared with 4.8 Ϯ 2.2 cells, respectively). On the other hand, transgenic mice manifested significantly more NSCs in the SVZ than did wild-type mice (p Ͻ 0.05). These regional differences might be attributable to the number of animals and cells. In the aging brain, there is an accumulation of oxidative DNA and lipid damage. 2, 3, 40 Transgenic mice overexpressing SOD1 such as those in our study showed attenuation of oxidative DNA damage during aging. 2 Taken together, these results suggest that SOD1, an endogenous antioxidant, may have an ability to preserve the proliferation of NSCs in aging mice to protect aging brain tissue from oxidative damage. In terms of the mechanisms of these effects, we propose the existence of both direct and indirect effects. The direct effect may act protectively on NSCs and preserve their ability to proliferate. The indirect effect may act on other cells that promote the proliferation of NSCs by releasing factors such as fibroblast growth factor, nerve growth factor, insulin-like growth factor-I, and vascular endothelial growth factor. 16, 17, 20, 23, 42 The attenuation of oxidative damage may be a significant factor in the proliferation of NSCs regardless of either direct or indirect effect.
Experiment 2: Acute Oxidative Stress
Because the preliminary data showed good expression of BrdU in the SVZ and DG, as well as a high survival rate in mice, we selected 30 minutes as the duration of MCAO for the transient focal cerebral ischemia model. Given that previous data have demonstrated peak expression of BrdU in NSCs following focal cerebral ischemia, we decided on 8 days after ischemic insults for the timing of our analysis. Although previous results showed a protective effect of SOD1 for transient focal cerebral ischemia, 21 there was no significant difference in the infarct volume between transgenic and wild-type mice by 8 days of reperfusion after a 30-minute MCAO in the present study. Furthermore, there was no cortical infarction in this model given the short period of MCAO. We suppose that the duration of focal cerebral ischemia was too short to detect the protective effect of SOD1 compared with that observed in the previous report (50-60 minutes).
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Copper/zinc superoxide dismutase and neural stem cells In rodent models of focal and global cerebral ischemia, the proliferation of NSCs has been reported. 18, 26, 31 Jin, et al., 18 found an increase in NSCs in the bilateral SVZ and DG in rats following focal cerebral ischemia. Parent, et al., 31 reported enhanced SVZ neurogenesis in the ischemic hemisphere following a 90-minute MCAO. Thus, although the dynamics of NSC proliferation after focal cerebral ischemia remain to be elucidated, the occurrence of neurogenesis in the SVZ and DG in the ischemic hemisphere has been established. Regarding neurogenesis in the contralateral, nonischemic hemisphere, the underlying mechanisms may involve transsynaptic and diffusible chemical effects. We observed SVZ and DG neurogenesis in the ischemic hemispheres in both transgenic and wild-type mice. Furthermore, although transgenic mice manifested significantly more NSCs in the DG than those in wild-type mice (p Ͻ 0.05), there was no significant difference in the number of NSCs in the SVZ between transgenic and wild-type mice. Arvidsson, et al., 1 reported that in adult rats subjected to focal cerebral ischemia, MK801 completely suppressed DG neurogenesis. Due to the presence of many N-methyl-D-aspartate receptors in the hippocampus, the DG is sensitive to glutamate insult. 11 The observed increase in DG neurogenesis in ischemic transgenic mice may be attributable to the effects of SOD1 on the glutamate concentration in the DG following focal cerebral ischemia. 1 Although SOD1 is known to exert a protective effect in transient focal cerebral ischemia, the mechanisms underlying the observed increase in NSCs in the SVZ and DG in ischemic transgenic mice remains to be elucidated. As in our aging study, these findings may suggest that SOD1 has direct and indirect effects. Human SOD1 was overexpressed in the cells of the SVZ and DG as well as in neurons and astrocytes in the cortex or the white matter in transgenic mice (data not shown); therefore, SOD1 can influence the dynamics of the NSC in conditions of aging and transient focal cerebral ischemia. We need to perform additional investigations to clarify mechanisms for the regulation of the level of stimulation by ischemic injury for the initiation of NSC proliferation and the protective effect of NSCs and any related cells by SOD1. We propose that focal cerebral ischemia might be only a trigger for the increase in NSCs rather than a promoter of neurogenesis.
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Bromodeoxyuridine labeling 24 hours before killing the animals showed that the BrdU-positive cells were not labeled by IB-4 as a marker of microglia. 25, 35 Given that BrdUpositive cells were labeled by NeuN and GFAP as the markers of mature neurons and astrocytes, our results indicated that BrdU-positive cells can be considered as NSCs.
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Conclusions
Our findings suggest that chronic and acute oxidative stress may suppress the enhanced proliferation of NSCs. It is likely that SOD1, through direct and/or indirect effects, plays a significant role in the proliferation of NSCs. Studies are underway in our laboratory to determine the mechanisms underlying the proliferation of NSCs.
